IL301047A - A method for treating amyloidosis - Google Patents
A method for treating amyloidosisInfo
- Publication number
- IL301047A IL301047A IL301047A IL30104723A IL301047A IL 301047 A IL301047 A IL 301047A IL 301047 A IL301047 A IL 301047A IL 30104723 A IL30104723 A IL 30104723A IL 301047 A IL301047 A IL 301047A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- subject
- dose
- amyloidosis
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Developmental Biology & Embryology (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078258P | 2020-09-14 | 2020-09-14 | |
| US202063116100P | 2020-11-19 | 2020-11-19 | |
| US202163176015P | 2021-04-16 | 2021-04-16 | |
| PCT/US2021/050316 WO2022056484A1 (en) | 2020-09-14 | 2021-09-14 | Method of treating amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301047A true IL301047A (en) | 2023-05-01 |
Family
ID=80631942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301047A IL301047A (en) | 2020-09-14 | 2021-09-14 | A method for treating amyloidosis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230364228A1 (https=) |
| EP (1) | EP4210753A4 (https=) |
| JP (1) | JP2023541191A (https=) |
| KR (1) | KR20230069161A (https=) |
| AU (1) | AU2021339851A1 (https=) |
| CA (1) | CA3192069A1 (https=) |
| IL (1) | IL301047A (https=) |
| MX (1) | MX2023002997A (https=) |
| WO (1) | WO2022056484A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022346750A1 (en) * | 2021-09-14 | 2024-04-11 | Caelum Biosciences, Inc. | Method of treating multiple myeloma |
| CN120322242A (zh) * | 2022-09-16 | 2025-07-15 | 联邦高等教育系统天普大学 | Bag3用于治疗心脏淀粉样变性的方法和用途 |
| WO2025194030A1 (en) | 2024-03-15 | 2025-09-18 | Alexion Pharmaceuticals, Inc. | Treatment of mayo stage iiib light chain amyloidosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5553963B2 (ja) * | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
| US20090028847A1 (en) * | 2007-04-12 | 2009-01-29 | Trustees Of Boston University | Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| PH12021552135A1 (en) * | 2019-03-05 | 2022-08-31 | Prothena Biosciences Ltd | Methods of treating al amyloidosis |
-
2021
- 2021-09-14 AU AU2021339851A patent/AU2021339851A1/en active Pending
- 2021-09-14 CA CA3192069A patent/CA3192069A1/en active Pending
- 2021-09-14 JP JP2023516809A patent/JP2023541191A/ja active Pending
- 2021-09-14 WO PCT/US2021/050316 patent/WO2022056484A1/en not_active Ceased
- 2021-09-14 MX MX2023002997A patent/MX2023002997A/es unknown
- 2021-09-14 US US18/026,185 patent/US20230364228A1/en active Pending
- 2021-09-14 KR KR1020237012401A patent/KR20230069161A/ko active Pending
- 2021-09-14 IL IL301047A patent/IL301047A/en unknown
- 2021-09-14 EP EP21867833.2A patent/EP4210753A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230364228A1 (en) | 2023-11-16 |
| JP2023541191A (ja) | 2023-09-28 |
| AU2021339851A1 (en) | 2023-04-13 |
| AU2021339851A8 (en) | 2023-04-20 |
| WO2022056484A1 (en) | 2022-03-17 |
| CA3192069A1 (en) | 2022-03-17 |
| EP4210753A1 (en) | 2023-07-19 |
| MX2023002997A (es) | 2023-05-11 |
| EP4210753A4 (en) | 2025-01-08 |
| KR20230069161A (ko) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260042861A1 (en) | Formulations of anti-cd38 antibodies for subcutaneous administration | |
| US20230340122A1 (en) | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer | |
| US20230364228A1 (en) | Method of treating amyloidosis | |
| EA029214B1 (ru) | Композиции антител и их применения | |
| CN111212662A (zh) | 治疗癌症的组合疗法 | |
| CA3110276A1 (en) | Treatment of triple negative breast cancer with targeted tgf-b inhibition | |
| AU2020341135A1 (en) | Treatment of liver disease or disorder comprising ActRII receptor antagonists | |
| JP2025508766A (ja) | Fcrnアンタゴニストを使用して筋炎を治療するための方法 | |
| CN118043072A (zh) | 治疗多发性骨髓瘤的方法 | |
| US20240392028A1 (en) | Method of treating multiple myeloma | |
| KR20240028452A (ko) | 암을 치료하기 위한 방법 및 조성물 | |
| EP4319809A1 (en) | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer | |
| US20220031840A1 (en) | Method of Treatment | |
| JP2025522729A (ja) | ガレクチン-9を阻害する抗体を用いた悪性血液疾患の処置 | |
| EA050760B1 (ru) | Способ лечения множественной миеломы | |
| CN116782935A (zh) | 治疗淀粉样变性的方法 | |
| IL295202A (en) | Anti-cd30 antibody-drug conjugates and their use for the treatment of non-Hodgkin's lymphoma | |
| US20250313618A1 (en) | Methods of treating giant cell arteritis using Interleukin-17 (IL-17) Antagonists | |
| JP2019505516A (ja) | インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法 | |
| JP2025515344A (ja) | 抗pd-1抗体と抗egfr抗体との組み合わせ及び頭頸部扁平上皮がんの治療におけるその使用 | |
| WO2026008043A9 (zh) | 靶向Nectin-4的抗体药物缀合物和免疫检查点抑制剂联合的用途 | |
| HK40109234A (zh) | 用於治疗癌症的方法和组合物 | |
| HK40110052A (zh) | 用於治疗癌症的方法和组合物 | |
| US20190247503A1 (en) | Methods for treating relapsing forms of multiple sclerosis | |
| WO2023107100A1 (en) | Methods and treatment for multiple myeloma involving antibodies to il-18 |